Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and serum tumor necrosis factor α in patients with ulcerative colitis

Voiosu, Theodor; Benguș, Andreea; Bălănescu, Paul; Dinu, Roxana; Voiosu, Andrei; Băicuș, Cristian; Mateescu, Bogdan

doi:10.1515/rjim-2015-0033

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This findings were consistent with Voiosu et al in which faecal calprotectin was a better predictor of mucosal healing than anti-TNF levels in a small population of 53 patients with UC. 17 Other studies comparing faecal calprotectin with biochemical markers such as CRP were also compatible with our study, [18][19][20] in which they also showed that CRP and platelet count correlated negatively while albumin correlated positively with anti-TNF levels.…”

Section: Discussionsupporting

confidence: 91%

The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease

Tan¹,

Neeman²,

Subramaniam³

2022

GHOA

View full text Add to dashboard Cite

Introduction: Although higher anti-tumour necrosis factor (anti-TNF) levels are associated with higher rates of clinical remission, much less is known regarding the associations between biomarkers and endoscopic findings in patients with inflammatory bowel disease (IBD). Methods & methods: A retrospective analysis of patients with available anti-TNF levels attending an IBD clinic at a tertiary centre from 1st January 2014 – 31st May 2020 was completed. Demographics, disease activity scores, endoscopic findings and biomarker data were collected. The area-under-curve (AUC) on the receiver operating characteristic curve was plotted to measure and compare the performance of variables in predicting endoscopic remission. This was supplemented by linear discriminant analysis. Results: One hundred and eighty patients were included. Faecal calprotectin was better at distinguishing between quiescent and active endoscopic disease than anti-TNF level .AUC 0.78 (95% CI 0.68 – 0.89) versus 0.62 (95% CI 0.48 – 0.75). Faecal calprotectin had a higher sensitivity (77% vs 50%) and specificity (71% vs 64%) compared to anti TNF levels in predicting endoscopic activity. We found that a faecal calprotectin threshold of 200ug/g and similarly an anti TNF level of 6.21ug/ml optimally predicts endoscopic disease. Using linear discriminant analysis, faecal calprotectin was weighted against C-reactive protein (CRP), albumin, platelet count, anti-TNF, and has shown to be better at predicting mild to moderate disease activity (Log FC=0.74). Conclusion: Faecal calprotectin as opposed to anti-TNF level is more likely to predict endoscopic disease activity. We plan to do a prospective study to confirm these findings and to develop a set of clinical cut-offs to improve disease management.

show abstract

Section: Discussionsupporting

confidence: 91%

The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease

Tan¹,

Neeman²,

Subramaniam³

2022

GHOA

View full text Add to dashboard Cite

show abstract

“…Low serum albumin levels, high serum CRP levels, and a high concentration of calprotectin in the feces are commonly used inflammatory markers that have been associated with the need for colectomy [3,17]. Patients who require hospitalization have a trend toward a lower serum albumin and higher CRP levels.…”

Section: Discussionmentioning

confidence: 99%

A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis

Yamagami

Nagami

et al. 2017

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

Introduction. Both infliximab (IFX) and tacrolimus (Tac) are effective for inducing clinical remission in patients with ulcerative colitis (UC). However, no randomized study has addressed the relative efficacies of IFX and Tac for patients with moderate to severe UC. This study aimed to conduct a retrospective study on the relative efficacy of IFX and Tac in patients with moderate to severe UC, using an inverse probability of treatment weighting (IPTW) technique to adjust background factors statistically.Methods. Between July 2009 and March 2016, data obtained from 122 patients with moderate to severe UC who were treated with either IFX (n = 58) or Tac (n = 64) were analyzed retrospectively. We compared the short-term therapeutic efficacy between the IFX group and Tac group using IPTW technique.Results. The clinical remission rate at 14 weeks after treatment was 37.9% (22/58) in the IFX group and 50% (32/64) in the Tac group, respectively. The efficacy of IFX and Tac for clinical remission rate was not different according to univariate (Odds ratio [OR] 1.64, 95% confidence interval [CI] 0.80-3.37 P = 0.18) and multivariate analyses (OR 2.19, 95% CI 0.85-5.61, P = 0.10). After the background and confounders factors were adjusted by using IPTW based on propensity score, the efficacy of IFX and Tac for clinical remission rate was not differed statistically (OR, 1.483; 95% CI, 0.581-3.785; P = 0.409) Conclusion. IFX and Tac have equivalent short-term efficacies for induction in patients with moderate to severe UC.

show abstract

Current and emerging biomarkers for ulcerative colitis

Nowak,

Kalla,

Satsangi

2023

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and serum tumor necrosis factor α in patients with ulcerative colitis

Abstract: Rapid calprotectin testing is a better predictor of mucosal healing than serum biomarkers and it could improve the management of ulcerative colitis patients by decreasing the need for invasive investigations.

Cited by 4 publications

References 41 publications

The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease

The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease

A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis

Current and emerging biomarkers for ulcerative colitis

Contact Info

Product

Resources

About